Peptide News Digest

#Taltz

1 story

Clinical Trials · View digest

Lilly's TOGETHER-PsA: 43.7% on Taltz Plus Zepbound vs. 15.7% on Taltz Alone Reached ACR50 at One Year in Psoriatic Arthritis With Obesity

In the open-label, assessor-blinded Phase 3b TOGETHER-PsA trial of 271 adults with active psoriatic arthritis and obesity or overweight with a weight-related condition, 43.7% of those taking Taltz with Zepbound and 15.7% of those on Taltz alone had at least a 50% reduction in disease activity (ACR50) at 52 weeks, Lilly said on November 11. The one-year comparisons are exploratory and not controlled for multiple testing; the Week 36 primary endpoint had already favored the combination. Results were presented at ACR Convergence 2026 and published in Arthritis & Rheumatology.